Current Report Filing (8-k)
July 02 2014 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
July 1, 2014
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware |
000-30975 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
91-1789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE |
68164 |
(Address of principal executive offices) |
(Zip Code) |
(402) 452-5400
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))
Item 7.01 Regulation FD Disclosure.
On July 1, 2014, the
Collaboration Agreement between Transgenomic, Inc. (“Transgenomic”) and PDI, Inc., a Delaware corporation d/b/a Interpace
Diagnostics, for the promotion of Transgenomic’s CardioPredict test expired automatically pursuant to its terms upon the
parties’ completion of phase one under the agreement. Transgenomic management believes that the test continues to have good
commercial potential and is evaluating commercialization options.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TRANSGENOMIC, INC. |
|
July 2, 2014 |
By |
/s/ Mark P. Colonnese |
|
|
|
Mark P. Colonnese
Executive Vice President and Chief Financial Officer |
|
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Apr 2023 to Apr 2024